Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ePIPAC-OX for unresectable colorectal peritoneal metastases
ISRCTN89947480Phase 2Completed
- Sponsor
- Catharina Ziekenhuis
- Start
- Oct 2017
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin, fluorouracil and folinic acid in colorectal cancer (CRC), Appendiceal carcinoma and peritoneal carcinomatosis (PC), sponsored by Catharina Ziekenhuis. Primary endpoint: Major toxicity. Started Oct 2017; status: completed.
02
Drugs
oxaliplatinfluorouracilfolinic acid
03
Conditions
colorectal cancer (CRC)Appendiceal carcinomaperitoneal carcinomatosis (PC)
Beyond the preview
Go deeper on ISRCTN89947480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN89947480.